Literature DB >> 12048667

Heterotopic ossification in critical illness and cancer: a report of 2 cases.

Ying Guo1, Christopher R Collaco, Eduardo Bruera.   

Abstract

Heterotopic ossification is the abnormal development of bone tissue within periarticular soft tissue. We present 2 Turkish patients with malignant thoracic cancer who underwent extensive thoracic surgery and required prolonged postoperative chemical paralysis and cardiorespiratory support for respiratory complications. Both patients were found by the physiatrist to have multiple, extensive heterotopic ossifications. Clinical findings in both patients included joint swelling and severe limitation in range of motion (ROM) associated with pain. The diagnoses were confirmed radiographically. After an extended length of inpatient rehabilitation, both patients improved their cumulative FIM instrument motor scores by 23 and were discharged with a trained family member. Our findings suggested that heterotopic ossification should be suspected in patients presenting with decreased ROM, increased pain, and joint swelling after prolonged immobilization. Serum alkaline phosphatase might be used as an effective screening tool. Copyright 2002 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12048667     DOI: 10.1053/apmr.2002.32440

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  2 in total

1.  Heterotopic ossification post COVID-19: Report of two cases.

Authors:  Amany Aziz; Rishabh Choudhari; Anup Jacob Alexander; Emad Allam
Journal:  Radiol Case Rep       Date:  2020-12-09

2.  Underlying Ossification Phenotype in a Murine Model of Metastatic Synovial Sarcoma.

Authors:  Matthew Kirkham; Austen Kalivas; Kaniz Fatema; Sarah Luelling; Brooke H Dubansky; Benjamin Dubansky; Kevin B Jones; Jared J Barrott
Journal:  Int J Mol Sci       Date:  2020-04-10       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.